AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

More tepid economic news and a pledge by Donald Trump to push through tariffs on top trading partners stressed Wall Street ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

A rebound in stocks sputtered as data showed US manufacturing approached stagnation amid jump in prices, deepening concerns about the outlook for the world’s largest economy.

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...